At the ceremony for Healthcare Investment Rankings 2018 at Hyatt on the Bund in Shanghai, on March 29, 2018. Abbisko was selected for the Best Innovative Biomedical Investment Case award. Mr. Yao-chang Xu, founder and Chairman of the Board of Abbisko, attended the ceremony and received the award. Nearly 400 specialized medical investment funds, listed companies, startups and media representatives witnessed the event together.

The Healthcare Investment Rankings is published annually by Healthcare Capital in the field of healthcare investment. By establishing a fair and objective evaluation mechanism and widely inviting professional institutional investors to vote by their real names, the Healthcare Investment Rankings is committed to creating a ranking list that is selected by data and votes and truly reflects the trends in healthcare investment. Among numerous biomedical investment cases in 2017, Abbisko secured a real-name majority vote from nearly 300 investment institutions and won the Best Biomedical Investment Case award in the Healthcare Investment Rankings 2018.

In addition, Mr. Yao-chang Xu attended the roundtable discussion on the “New Opportunities in Hong Kong Market and in Biomedicine” as a guest and shared his opinions. Mr. Xu says biomedical companies have been on the NASDAQ market for decades. Through the joint efforts of enterprises, investors, retail investors, regulators and trading companies, a relatively mature system has been formed. However, a series of mechanisms still need to be improved for the listing of biomedical companies on the Hong Kong Stock Exchange. For example, what kind of information disclosure systems do biomedical companies need? How do investors respond to the risks of new drug development? These are issues that require further discussion and validation in the future.